Recursion: Path Forward For REC-994 Remains Despite Mixed Response [Seeking Alpha]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Seeking Alpha
Terry Chrisomalis Investing Group Leader Follow Summary Recursion Pharmaceuticals, Inc.'s REC-994 was able to show positive safety/tolerability data for the treatment of Cerebral Cavernous Malformation, along with a trend towards improvement. End-of-phase 2 meeting with FDA will shed more light on required approval efficacy endpoint for CCM and other trial changes to move forward with, like higher dosing and longer-duration treatment. REC-2282 for Neurofibromatosis Type 2 and REC-4881 for Familial Adenomatous Polyposis are other programs being advanced; Data from each expected Q4 of 2024 and 1st half of 2025 respectively. REC-4881 can also be developed to treat patients with advanced AXIN1/APC-mutated cancers; Data from this program to be released in the 1st half of 2025. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » gorodenkoff/iStock via Getty Images I beli
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock [Yahoo! Finance]Yahoo! Finance
- Recursion Stock Down Despite Meeting Goal in Brain Disease Study [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its price target lowered by analysts at Leerink Partners from $9.00 to $8.00. They now have a "market perform" rating on the stock.MarketBeat
RXRX
Earnings
- 8/8/24 - Miss
RXRX
Sec Filings
- 9/26/24 - Form 144
- 9/19/24 - Form 4
- 9/19/24 - Form DEFA14A
- RXRX's page on the SEC website